Disease Overview：Monoclonal Gammopathy（MG）
Monoclonal gammopathy is a hematologic disorder characterized by the abnormal proliferation of plasma cells that produce a single, homogeneous immunoglobulin (M protein) detectable in serum or urine. While monoclonal gammopathy of undetermined significance (MGUS) is often asymptomatic and monitored expectantly, it may progress to more serious conditions such as multiple myeloma, Waldenström macroglobulinemia, or AL amyloidosis—requiring timely diagnosis and risk-stratified intervention. Diagnosis relies on serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), quantitative immunoglobulins, free light chain assay, and bone marrow biopsy with flow cytometry and cytogenetic analysis. Risk assessment incorporates ISS staging, high-risk cytogenetics (e.g., del(17p), t(4;14)), and tumor burden markers.
China offers compelling advantages for international patients seeking care: leading hematology centers—such as Peking University People’s Hospital and Ruijin Hospital—boast internationally trained specialists with deep expertise in plasma cell disorders and access to next-generation sequencing, minimal residual disease (MRD) monitoring via next-generation flow cytometry, and FDA/EMA-approved novel agents including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. Clinical trial participation rates are high, and real-world outcomes align closely with global benchmarks. Treatment costs in China average 40–60% lower than in the US or Western Europe, without compromising quality—particularly for prolonged maintenance therapy or complex procedures like autologous stem cell transplantation.
As a dedicated medical tourism agency, we facilitate seamless cross-border care: coordinating appointments with top-tier hematologists, verifying hospital accreditation and treatment protocols, providing itemized, transparent pricing in advance, and offering end-to-end support—from visa assistance and medical translation to accommodation and post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Monoclonal Gammopathy (Hematology)
Non-Surgical / Conservative / Medication Options
*Indicated for asymptomatic MGUS, smoldering multiple myeloma (SMM), or low-risk monoclonal gammopathy of renal significance (MGRS) without end-organ damage.*
- •Active Surveillance (MGUS/SMM)
- *Annual monitoring:* CBC ($25), serum protein electrophoresis + immunofixation ($45), free light chain assay ($38), creatinine/eGFR ($12), calcium ($8), skeletal survey (X-ray, 4 views) ($65) → $193/year
- •First-Line Pharmacotherapy (Symptomatic MGRS or early MM)
- *Regimen:* Lenalidomide 25 mg/day × 21 days + low-dose dexamethasone ($1,280/cycle) - *Supportive care:* IV bisphosphonate (zoledronic acid, $145/dose), erythropoietin if anemia ($85/injection), antiviral prophylaxis (acyclovir, $12/month) - *Cycle 1 total (incl. labs & monitoring):* $1,580
Surgical / Procedural / Interventional Options
*Strictly hematologic interventions; no ophthalmic procedures.*
- •Autologous Stem Cell Transplant (ASCT)
- *Pre-op workup:* PET-CT ($420), echocardiogram ($75), pulmonary function test ($60), infectious serologies ($48), CD34+ cell mobilization (G-CSF + plerixafor, $1,120) → $1,723 - *Procedure & hospitalization (21-day inpatient):* Conditioning (melphalan 200 mg/m², $310), apheresis ($290), reinfusion, supportive care → $14,850
- •Plasmapheresis (Acute Hyperviscosity or Rapidly Progressive MGRS)
- *Per session (3–5 sessions typical):* Vascular access + 3-hour procedure + albumin replacement → $490/session
Special / Complex Condition Management
- •High-Risk Cytogenetic MM (del17p, t(4;14), t(14;16)): Daratumumab + lenalidomide + dexamethasone → $4,250/cycle (includes IV infusion, nursing, premeds)
- •AL Amyloidosis (Monoclonal Light Chain–Driven): Bortezomib + cyclophosphamide + dexamethasone + cardiac biomarker monitoring → $2,960/cycle
- •Relapsed/Refractory Disease (≥3 prior lines): BCMA-targeted CAR-T (e.g., CT053) — $128,000 (single infusion, includes lymphodepletion, 28-day inpatient monitoring)
Quick Selection Guide
- •Age <65, fit, newly diagnosed MM: ASCT — optimal PFS/OS benefit despite upfront cost ($16,573 total).
- •Age ≥75 or significant comorbidities (COPD, HF, CKD stage 4): Lenalidomide/dexamethasone — lower toxicity, $1,580/cycle, outpatient.
- •MGUS/SMM, budget-constrained: Active surveillance — $193/year, evidence-based for low-risk disease.
- •Acute renal failure from MGRS: Urgent plasmapheresis ($490/session × 3) + rapid initiation of chemotherapy — prevents dialysis dependence.
- •High-risk cytogenetics or extramedullary disease: Early daratumumab-based regimen — improves depth/duration of response despite higher per-cycle cost.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Monoclonal Gammopathy Medical Vacation Packages
Curated transparent all-inclusive packages combining Monoclonal Gammopathy treatment with China top medical destinations:
